In making its decision, the body said the case for doing so put forward by Danish pharmaceutical company Novo Nordisk "had poorly justified the population access it had requested, the modelled benefits were highly uncertain, and the listing would not be cost-effective at the requested price"
For Hashimoto's specifically, the question is whether improving insulin sensitivity, reducing visceral fat, and lowering inflammatory markers could slow the autoimmune destruction of thyroid tissue
Vitamins & Nutritional Health
La ricerca di Da Qing non ha valutato direttamente la perdita di peso, ma suggerisce che anche un intervento di durata relativamente breve potrebbe generare benefici duraturi
Brown GC, Vilalta A (2015) How microglia kill neurons
Cost and insurance coverage are also real barriers for many patients